What is Allogene Therapeutics's cumulative cost basis?

Allogene Therapeutics (ALLO) reported cumulative cost basis of $261.82M in Q1 2026.

How has Allogene Therapeutics's cumulative cost basis changed year-over-year?

Allogene Therapeutics's cumulative cost basis decreased by 20.9% year-over-year, from $331.19M to $261.82M.

What is the long-term trend for Allogene Therapeutics's cumulative cost basis?

Over 5 years (2020 to 2025), Allogene Therapeutics's cumulative cost basis has grown at a -23.1% compound annual growth rate (CAGR), from $950.1M to $254.87M.

Allogene Therapeutics ALLO Cumulative Cost Basis

Cumulative Cost Basis at other companies

Gilead SciencesGILD

——

PrecigenPGEN

——

Artiva Biotherapeutics, Inc.ARTV

——

Arcus BiosciencesRCUS

——

Vir Biotechnology, Inc.VIR

——

Other financials

Income statement

See full

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

See full

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Total assets$396.0M-22.1%

Cash flow

See full

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

See full

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

See full

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Allogene Therapeutics's cumulative cost basis?: Allogene Therapeutics (ALLO) reported cumulative cost basis of $261.82M in Q1 2026.
How has Allogene Therapeutics's cumulative cost basis changed year-over-year?: Allogene Therapeutics's cumulative cost basis decreased by 20.9% year-over-year, from $331.19M to $261.82M.
What is the long-term trend for Allogene Therapeutics's cumulative cost basis?: Over 5 years (2020 to 2025), Allogene Therapeutics's cumulative cost basis has grown at a -23.1% compound annual growth rate (CAGR), from $950.1M to $254.87M.